you are here: Home News Dr Reddy

Dr Reddy

Dr Reddy’s: Is the weight loss drug the next big opportunity?
Adani Infra, Tata Power, Dr.Reddy, JSW Steel in Focus
Why should one avoid fresh bets on Dr Reddy’s?
Dr Reddy's Laboratories incorporates wholly-owned subsidiary in Jamaica; stock rises 1%
Who makes a better suitor for Cipla and what is in it for shareholders?
Another great quarter for Dr Reddy’s, but is it sustainable?
Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug
Cash Trade | Dr Reddy's bouncing off channel support
Markets extend rally to 3rd day; Sensex climbs over 300 points
Dr Reddy’s: Acceleration in EM opportunity to help re-rate company
Dr Reddy’s: Improving exposure to EMs adds to investment case
COVID-19 vaccine | India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light
Deregulation of vaccine rollout: What it means for pharma players
Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?
COVID Vaccine: The opportunities for investors - Part I
Cadila: a formidable play in Covid times and beyond
Ideas For Profit | Dr Reddy’s: An opportunity for risk takers
Dr Reddy's to recall 1,752 bottles of heartburn drug in the US
Dr Reddy's launches generic lipid-regulating tablets in US
Rising stars? 14 stocks reported over 100% surge in PAT
Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations
Dr Reddy’s Labs falls 4% as US FDA issues 11 observations to Bachupally plant
Upbeat CLSA view, procedural observations from US FDA send DRL stock up 3%
Dr Reddy’s tanks 6% on dismal Q1; brokerages turn cautious on stock
Dr Reddy’s US FDA developments get a thumbs up from brokerages

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Dr Reddy

Dr Reddy’s: Is the weight loss drug the next big opportunity?

Adani Infra, Tata Power, Dr.Reddy, JSW Steel in Focus

Why should one avoid fresh bets on Dr Reddy’s?

Dr Reddy's Laboratories incorporates wholly-owned subsidiary in Jamaica; stock rises 1%

Who makes a better suitor for Cipla and what is in it for shareholders?

Another great quarter for Dr Reddy’s, but is it sustainable?

Dr Reddy’s completes phase 1 study of key anti-rheumatic biosimilar drug

Cash Trade | Dr Reddy's bouncing off channel support

Markets extend rally to 3rd day; Sensex climbs over 300 points

Dr Reddy’s: Acceleration in EM opportunity to help re-rate company

Dr Reddy’s: Improving exposure to EMs adds to investment case

COVID-19 vaccine | India's Dr. Reddy's in talks with government to bring Russia's Sputnik Light

Deregulation of vaccine rollout: What it means for pharma players

Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

COVID Vaccine: The opportunities for investors - Part I

Cadila: a formidable play in Covid times and beyond

Ideas For Profit | Dr Reddy’s: An opportunity for risk takers

Dr Reddy's to recall 1,752 bottles of heartburn drug in the US

Dr Reddy's launches generic lipid-regulating tablets in US

Rising stars? 14 stocks reported over 100% surge in PAT

Dr Reddy’s plummets 23% as Jefferies red flags ‘repeat’ observations

Dr Reddy’s Labs falls 4% as US FDA issues 11 observations to Bachupally plant

Upbeat CLSA view, procedural observations from US FDA send DRL stock up 3%

Dr Reddy’s tanks 6% on dismal Q1; brokerages turn cautious on stock

Dr Reddy’s US FDA developments get a thumbs up from brokerages